ACSL4-Driven Ferroptosis Susceptibility in AML Cell Lines and Patient Specimens

15 adult AML cell lines screened with 6,790 compounds and CRISPR dependencies for 18,435 genes, integrated with ex vivo drug-response data from 476 primary AML specimens. The dataset, authored by Federico De Marchi and published on figshare in 2026, links ACSL4 expression to SRC kinase inhibition sensitivity and BCL2 inhibitor resistance.

Use Cases

• Identify drug-gene co-dependencies in AML based on integrated PRISM and CRISPR screening data.
• Validate therapeutic vulnerabilities in primary AML specimens based on ex vivo drug-response data from 476 samples.
• Associate ACSL4-driven ferroptosis susceptibility with clinical outcomes based on analysis of 140 adults with de novo AML.
• Stratify patient survival risk based on a composite SRC/ACSL4 gene expression signature.
• Investigate lineage-specific metabolic dependencies linking monocytic AML to ferroptosis and BCL2 inhibitor failure.

Strengths

• Integrated data from multiple sources: PRISM drug-sensitivity (6,790 compounds), DepMap CRISPR dependencies (18,435 genes), and ex vivo validation in 476 primary specimens.
• Multi-cohort validation strategy filters 50 discovery candidates through clinical outcomes in 140 adult AML patients.
• Clear statistical correlations reported, such as dasatinib sensitivity (r = -0.25, P = 4.3 x 10^-8) and venetoclax resistance (r = 0.36, P = 2.5 x 10^-12).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is presented in a PDF format (314.3 KB), which may require extraction for computational analysis.

Provenance

Source

figshare

Collection Method

Integrated analysis of PRISM drug-sensitivity data, DepMap CRISPR dependencies, and ex vivo drug-response data from primary AML specimens.

Freshness

Last updated 2026-05-22 04:27:59; freshness should be verified.